ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept (also known as ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
Location: United States, California, South San Francisco
Member count: 11-50
Total raised: $105M
Founded date: 2015

Investors 6

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
12.02.2020Series C$105M-fiercebiot...

Mentions in press and media 3

12.02.2020ALX Oncolo...---lightstone...
12.02.2020ALX raises...ALX Oncology has raised $105 m...Biotech-fiercebiot...
12.02.2020ALX Oncolo...The company plans to invest th...--medcitynew...